Novadaq Technologies Inc. (NVDQ) Analysts See $-0.21 EPS

July 18, 2017 - By Vivian Park

 Novadaq Technologies Inc. (NVDQ) Analysts See $ 0.21 EPS

Analysts await Novadaq Technologies Inc. (NASDAQ:NVDQ) to report earnings on July, 26. They expect $-0.21 earnings per share, up 27.59 % or $0.08 from last year’s $-0.29 per share. After $-0.24 actual earnings per share reported by Novadaq Technologies Inc. for the previous quarter, Wall Street now forecasts -12.50 % EPS growth. The stock increased 0.09% or $0.01 during the last trading session, reaching $11.72. About 537,172 shares traded. Novadaq Technologies Inc. (NASDAQ:NVDQ) has declined 24.90% since July 18, 2016 and is downtrending. It has underperformed by 41.60% the S&P500.

Novadaq Technologies Inc. (NASDAQ:NVDQ) Ratings Coverage

Among 10 analysts covering Novadaq Technologies Inc (NASDAQ:NVDQ), 1 have Buy rating, 0 Sell and 9 Hold. Therefore 10% are positive. Novadaq Technologies Inc had 19 analyst reports since October 7, 2015 according to SRatingsIntel. The firm has “Overweight” rating by First Analysis given on Thursday, October 29. Stifel Nicolaus downgraded the shares of NVDQ in report on Tuesday, June 20 to “Hold” rating. Wedbush initiated the shares of NVDQ in report on Wednesday, October 7 with “Outperform” rating. The firm earned “Buy” rating on Monday, June 19 by Canaccord Genuity. First Analysis downgraded the shares of NVDQ in report on Tuesday, June 20 to “Hold” rating. On Thursday, July 13 the stock rating was downgraded by RBC Capital Markets to “Hold”. On Monday, July 10 the stock rating was downgraded by Canaccord Genuity to “Hold”. The rating was maintained by Wedbush with “Outperform” on Wednesday, January 11. The stock has “Market Perform” rating by William Blair on Wednesday, January 11. As per Wednesday, January 6, the company rating was initiated by JMP Securities.

NOVADAQ Technologies Inc. is a medical device company. The company has market cap of $677.10 million. The Firm primarily develops, makes and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. It currently has negative earnings. The Company’s SPY fluorescence imaging technology platform provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic.

More news for Novadaq Technologies Inc. (NASDAQ:NVDQ) were recently published by: Fool.com, which released: “Why Novadaq Technologies Inc. Skyrocketed Yesterday” on June 20, 2017. Nasdaq.com‘s article titled: “NOVADAQ Mails Information Circular for Special Meeting of Shareholders” and published on July 12, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: